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Eukaryotic cells produce a family of diverse inositol
polyphosphates (IPs) containing pyrophosphate
bonds. Inositol pyrophosphates have been linked to
awide rangeof cellular functions, and there isgrowing
evidence that they act as second messengers. Inosi-
tol hexakisphosphate kinase (IP6K) is able to convert
the natural substrates inositol pentakisphosphate
(IP5) and inositol hexakisphosphate (IP6) to several
products with an increasing number of phospho-an-
hydride bonds. In this study, we structurally analyzed
IPs synthesized by three mammalian isoforms of
IP6K from IP5 and IP6. The NMR and mass analyses
showed a number of products with diverse, yet spe-
cific, stereochemistry, defined by the architecture of
IP6K’s active site. We now report that IP6K synthe-
sizes both pyrophosphate (diphospho) as well as tri-
phospho groups on the inositol ring. All three IP6K
isoforms share the same activities both in vitro and
in vivo.
INTRODUCTION
The inositol ring offers an energetically stable base for the forma-
tion of a great variety of phosphorylated inositol derivatives.
Among nine possible isomers, the myo configuration of inositol
is the most widespread and versatile in biological systems (re-
viewed in Irvine and Schell, 2001; Michell, 2007). Although the
importance of the inositol trisphosphate (1,4,5)IP3 as a Ca
2+-mo-
bilizing second messenger was demonstrated in the early 1980s
(Streb et al., 1983), the first direct observations of inositol poly-
phosphates (IPs) containing diphosphate or pyrophosphate
groups were made in the early 1990s (Menniti et al., 1993a; Ste-
phens et al., 1993; Glennon and Shears, 1993). The distinctive
features of these inositol pyrophosphates (PP-IPs) are their rapid
turnover through coupled kinase/phosphatase cycles (Menniti
et al., 1993a, 1993b), and the high energy of the pyrophosphate
bonds (Stephens et al., 1993; Hand and Honek, 2007), suggest-274 Chemistry & Biology 15, 274–286, March 2008 ª2008 Elsevier Ling their importance in cell physiology and metabolism. PP-IPs
manifest several functions: regulating DNA recombination, telo-
mere length maintenance, response to stress, vesicular traffick-
ing, chemotaxis, and apoptosis (reviewed in Bennett et al.,
2006). These actions reflect either binding of PP-IPs to particular
protein domains (Ye et al., 1995; Luo et al., 2003) or modification
of proteins by phosphorylation (Saiardi et al., 2004).
Intracellular concentrations of PP-IPs are in the submicro-
molar range in mammalian and yeast cells, but they approach
100–200mMinslimemoldsduring starvation-inducedaggregation
(Laussmann et al., 2000). NMR studies of PP-IPs from several
species of amoeba reveal the structures of two major PP-IPs,
diphosphoinositol pentakisphosphate (PP-IP5 or IP7) and bis-
diphosphoinositol tetrakisphosphate ([PP]2-IP4 or IP8) (Lauss-
mann et al., 1996, 1997, 1998), both of which display variable
stereochemistry. In several species of Dictyostelium, the most
abundant IP7 isomer (90%) is 6-PP-(1,2,3,4,5)IP5 (or simply
6-PP-IP5), and the minor isomer is 5-PP-IP5, whereas the major
IP8 isomer is 5,6-[PP]2-IP4 (Laussmann et al., 1998). By contrast,
in Polysphondylium, 5-PP-IP5 is the prevalent IP7 (70%), with
6-PP-IP5 making up 30%. Besides the major IP8 isomer 5,6-[PP]2-
IP4 (75%), 25% of IP8 is 1(3),5-[PP]2-IP4 (Laussmann et al.,
1998). (Enantiomer positions C1/C3 and C4/C6 of the inositol
ring cannot be distinguished by NMR. For simplicity, the enantio-
mer positions are written within brackets, i.e., 1(3),5-[PP]2-IP4)
throughout the text.) While these compounds are all of the myo
configuration, the only non-myo PP-IPs identified to date by
NMR are from lysates of Entamoeba histolytica (2-PP-neo-IP5,
and 2,5-[PP]2-neo-IP4) (Martin et al., 2000). No structures of
PP-IPs isolated from mammalian cells have been reported thus
far. Chromatographic comparison of the lysates from several
mammalian cell lines (Albert et al., 1997) with IP7 standards
suggests that the major IP7 species is 5-PP-IP5.
PP-IPsaresynthesizedmainly fromtwonaturally abundantpre-
cursor molecules, myo-inositol pentakisphosphate (1,3,4,5,6)IP5
(IP5) and myo-inositol hexakisphosphate (IP6) (reviewed in Irvine
and Schell, 2001; Shears, 2004). Inositol hexakisphosphate ki-
nase (IP6K) was the first enzyme identified to synthesize PP-IPs
from IP5 and IP6, byutilizingATPasaphosphatedonor (Voglmaier
et al., 1996; Saiardi et al., 1999, 2000, 2001a; Schell et al., 1999).
Mammalian cells contain three isoforms of IP6K designatedtd All rights reserved
Chemistry & Biology
Catalytic Promiscuity of IP6KIP6K1, IP6K2, and IP6K3. Homologs in yeast, named Kcs1
(Saiardi et al., 1999), and in Dictyostelium (Luo et al., 2003) have
been identified, and a gene encoding IP6K occurs in the genome
of the early eukaryote Giardia (reviewed in Irvine, 2005). PP-IPs
have been found in plants, although no IP6K-like enzyme has
yet been identified. In vitro, all mammalian IP6Ks phosphorylate
IP6 to IP7 and IP8, and IP5 to PP-IP4 and [PP]2-IP3 (reviewed in
Bennett et al., 2006).
IP6Ks belong to the superfamily of inositol phosphate kinases
(IPK) (Irvine and Schell, 2001). Another member of the IPK super-
family, inositol phosphate multikinase (IPMK or IPK2), synthe-
sizes PP-IPs from IP5 (Saiardi et al., 2001b; Zhang et al., 2001;
Nalaskowski et al., 2002). In addition, enzymes not related to
the IPK superfamily also generate PP-IPs. Recently, the S. cere-
visiae protein Vip1 (Mulugu et al., 2007) was shown to possess
IP6/IP7 and (1,2,3,4,5)IP5-kinase activity, and NMR analyses
suggest that IP7, synthesized by human IP6K1 and yeast Vip1,
is 5-PP-IP5 and 4(6)-PP-IP5, respectively. Two Vip1-like proteins
were found in mammalian cells (Fridy et al., 2007; Choi et al.,
2007). Thus, PP-IPs in eukaryotic cells reflect the sum of the
activities of at least three families of kinases, IP6Ks, IPMK, and
the Vip1-like kinases.
To elucidate the contribution of IP6Ks to the pool of PP-IPs in
mammalian cells, we have conducted a detailed structural anal-
ysis of the products made by all three IP6Ks from IP5 and IP6. We
show that the three IP6K isoforms share the same activities both
in vivo and in vitro. The promiscuous activity of mammalian
IP6Ks leads to products of diverse, yet specific, stereochemis-
try. A most compelling finding is that IP6K does not only synthe-
size pyrophosphate bonds, but it also introduces triphosphate
groups on both IP5 and IP6.
RESULTS
The Activities of All Three IP6K Isoforms
Are Similar In Vivo and In Vitro
We compared the catalytic activities of all threemammalian IP6K
isoforms in vivo and in vitro. IP6K1, IP6K2, and IP6K3 were indi-
vidually overexpressed in a mutant strain of S. cerevisiae lacking
endogenous IP6 kinase (kcs1D). The introduction of any IP6K iso-
form into kcs1D resulted in the appearance of three new IPs elut-
ing after IP6, designated IP7, IP8A, and IP8B (Figure 1A). Elution
conditions used in the HPLC analysis resulted in comparable dif-
ferences in the elution times between IP6, IP7, and IP8, consistent
with the subsequent addition of phosphate groups. However, the
difference in elution between the peaks for IP8A and IP8B is much
smaller, suggesting the existence of IP8 isomers.
Lysates of wild-type yeast display IP7 and IP8A, but not IP8B
(Figure 1B). When IP6K2 is overexpressed in these cells, the
concentration of IP8B is significantly increased (Figure 1B).
The peaks for IP7 and IP8A synthesized in yeast cells by IP6Ks
overlap with the peaks of IPs produced in vitro by IP6K2 (Fig-
ure 1A). While no distinct peak for IP8B is detected in vitro, we
observe a more polar product, with a retention time suggesting
that it possesses one phosphate group more than IP8, which
we designate IP9 (Figure 1A). This IP can be detected only after
prolonged incubation of IP6 with IP6K. IP9 has also been ob-
served with in vivo experiments, but only under special labeling
conditions (A.S., unpublished data).Chemistry & Biology 1vip1Dkcs1D yeast were prepared in order to exclude the con-
tribution of both known yeast IP6/IP7 kinases, Kcs1 and Vip1.
When IP6K1 is overexpressed in these cells, both IP8A and IP8B
are formed, in addition to IP7 (Figure 1C, middle panel). In the
case of IP6K2, IP8A and IP8B merge into one peak (IP8, Figure 1C,
bottompanel). Since IP6K2behaves similarly to IP6K1 and IP6K3
in all other assays (Figure 1), this broad peak is probably due to
the impaired column resolution.
To study the in vivo activity of IP6K toward IP5 as a substrate, all
three IP6K isoforms were overexpressed in the double knockout
ipk1Dkcs1D yeast. In addition to the loss of Kcs1, this yeast strain
lacks Ipk1, the enzyme that synthesizes IP6 from (1,3,4,5,6)IP5
(York et al., 1999), thus allowing the accumulation of IP5 in these
cells (Saiardi et al., 2002). IP6Ks overexpressed under such
conditions utilize IP5 to form three main products of increasing
polarity, designated A, B, andC (Figure 1D). Differences in elution
times between the products (IP5 to A, A to B, and B to C) are sim-
ilar, suggesting a uniform difference in polarity between succes-
sive compounds due to the addition of one phosphate group at
a time. Peak A is split, similar to IP8A/IP8B, suggesting the pres-
ence of two isomers with different stereochemistry. The exis-
tenceof isomersof thepyrophosphorylated IP5-derivedproducts
(PP-IP4 or A in this case) has been previously reported (Zhang
et al., 2001; Perera et al., 2004). Twin peaks indicating the exis-
tence of isomers are also detected for product C, but only in
the case of IP6K2 (Figure 1D).
In the experiments described above, radiolabeled IPs were
used to determine IP6K activity in vivo and in vitro. Due to the un-
availability of 3[H]IP5, in vitro activities of IP6K isoforms toward
IP5 were determined by using a nonradioactive assay. As de-
scribed in the following section, the conversion of IP5 by IP6Ks
in vitro is highly comparable with in vivo conditions.
In addition to similar in vivo and in vitro activities of the
enzymes, the formation of IP7 and IP8, or A, B, and C, is very con-
sistent between independently performed assays. Thus, large-
scale in vitro synthesis of IPs for the structural analysis of IP6K
products can employ any IP6K isoform.
Development of a Nonradioactive Method Combining
HPLC with Inductively Coupled Plasma
Mass Spectrometry
Mammalian IP6K1, IP6K2, and IP6K3were overexpressed in and
purified from E. coli. The three enzymes were assayed with the
nonradiolabeled IP5 and IP6. IP6K1 and IP6K2, purified to
>95% purity, show comparable activity toward both substrates.
IP6K3 exhibits slightly weaker activity (Figures 2A and 2B), which
could be due to the limited purity (60%) of the protein.
HPLC based on ion-pair chromatography combined with
inductively coupled plasma mass spectrometry (ICP-MS) as
the detection system was used to analyze the assay mixtures.
ICP-MS was adjusted to continuously detect phosphorus-
containing compounds eluted from the column.
With IP6 as a substrate, IP6Ks consistently produce two peaks,
IP7 and IP8A (Figure 2A), under the assay conditions used in this
study. Since IP8A is the only IP8 isomer in vitro, it is referred to
as IP8 for the rest of the paper.
A time course analysis of product formation by IP6K2 carried
out over 4 hr at 37C reveals almost complete conversion of IP6
to IP7 in 20 min (Figure 2C). IP8 levels increase only after5, 274–286, March 2008 ª2008 Elsevier Ltd All rights reserved 275
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Catalytic Promiscuity of IP6KFigure 1. Activity of IP6Ks Overexpressed in Yeast
(A) kcs1D yeast. Top to bottom: control (empty pADH plasmid); overexpression of IP6K1, IP6K2, and IP6K3; in vitro activity of IP6K2 with IP6, 0.5 hr and 2 hr
assays.
(B) Wild-type (WT) yeast. Top to bottom: control (empty pADH plasmid); overexpression of IP6K2.
(C) vip1Dkcs1D yeast. Top to bottom: control (empty pADH plasmid); overexpression of IP6K1 and IP6K2.
(D) ipk1Dkcs1D yeast. Top to bottom: control (empty pADH plasmid); overexpression of IP6K1, IP6K2, and IP6K3; for comparison, ipk1D yeast. Chromatographic
analysis of the radiolabeled IPs on a PartiSphere SAX column is shown.a significant reduction in the IP6 concentration, suggesting that
IP8 is formed from the newly synthesized IP7. Slow synthesis
of IP8 might be due to a higher affinity of the IP6K active site for
IP6 compared with IP7 as a substrate or to the lower solubility of
IP8 under the assay conditions. A product of higher polarity
than IP8, possibly IP9, was detected only after prolonged incuba-
tion (12 hr or more).
With IP5 as a substrate, IP6K1 and IP6K2 consistently gener-
ate three products with increasing polarity (Figure 2B). IP6K3
forms only the first two products (Figure 2B), most likely due to
its generally lower activity. The peaks were assigned as in Fig-
ure 1D as A, B, and C. A always elutes as a single peak when
using HPLC-ICP-MS, in contrast to the split peak in Figure 1D.
As shown later, NMR studies reveal two compounds of similar
polarity within peak A. With prolonged assays (beyond 12 hr),
we detect two peaks close to the position of peak C (data not
shown), resembling the IP6K2 elution profile in Figure 1D.276 Chemistry & Biology 15, 274–286, March 2008 ª2008 Elsevier LThe time course of product formation by IP6K2 from IP5 is
shown in Figure 2D. Similar to the time course analysis for IP6,
each new product seems to represent a potential substrate for
IP6K in another round of phosphorylation.
Partial Inhibition of IP6K Activity by Cacodylate
While screening for the optimal buffer system to be used in IP6K
assays, we noticed partial inhibition of IP6K activity with increas-
ing concentrations of cacodylate buffer (data not shown). At
20mM, the concentration of buffer used in the assays, IP6 is con-
verted only to IP7 and IP5 is converted only to A (Figures 3E and
4B), and the amount of product formed is lower than in Tris buffer
(50%–60%). The inhibition is not pH dependent, since the pH of
the assay mixtures containing Tris or various concentrations of
cacodylate is always in the range in which IP6K is maximally ac-
tive (i.e., pH 7.5). A separate set of experiments also showed that
cacodylate does not inhibit pyruvate kinase/lactate hydrogenasetd All rights reserved
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Catalytic Promiscuity of IP6KFigure 2. Determination of the In Vitro Activity of IP6K Isoforms by Using a Nonradioactive Method
(A) HPLC-ICP-MS analysis of the IP6K assay mixture with IP6 (120 mM IP6, 1 mMMgCl2, 12 hr at 37
C). IP6K1, red; IP6K2, blue; IP6K3, green; control with bovine
serum albumin (BSA), black, dashed line. The IP8 elution profile is enlarged for clarity.
(B) HPLC-ICP-MS analysis of the IP6K assay mixture with IP5 (250 mM IP5, 1.5 mMMgCl2, 4 hr at 37
C). IP6K1, red; IP6K2, blue; IP6K3, green; control with BSA,
black, dashed line. Elution times for IP6, IP7, and IP8 are marked.
(C) Time course of IP6 conversion by IP6K2 (120 mM IP6, 1 mM MgCl2). IP6, black; IP7, red; IP8, blue.
(D) Time course of IP5 conversion by IP6K2 (250 mM IP5, 1.5 mM MgCl2). IP5, black; A, blue; B, red; C, green.(PK/LDH), used as an ATP-regeneration system in the enzyme
assay (data not shown).
This serendipitous discovery of the partial inhibition of IP6K by
cacodylate was later used to an advantage in the structural
studies of the IP6K products from assay mixtures.
Structural Analysis of Compounds Synthesized by IP6K
The structures of IPs made by IP6K from IP5 and IP6 were deter-
mined by a combination of NMR and electrospray ionization-
mass spectrometry (ESI-MS) (Table 1). All samples analyzed
by NMR were adjusted to pH 6.0–6.1. The samples were tested
for their integrity throughout sample preparation and after NMR
data collection by using HPLC-ICP-MS, and no significant
changes over timewere seen. The IP structureswere determined
from 1H-decoupled 31P, 1H-31P Heteronuclear Multiple Bond
Correlation with gradients for coherence selection (gHMBC),
and 1H-1H Double Quantum Filtered-Correlation Spectroscopy
(DQF-COSY) spectra.
NMR spectra crucial for the understanding of IP structure
determination are described in the main text. A more detailed
presentation of spectra is provided in the Supplemental Data
available with this article online.Chemistry & Biology 1IP6 Is Utilized by All Three IP6Ks in the Same Manner
to Form IP7 with a Structure of 5-PP-IP5
First, HPLC-purified IP7 produced by IP6K1 was analyzed.
1H-decoupled 31P and 1H-31P gHMBC spectra (Figures 3A and
3C) for pure IP6 as well as HPLC-purified IP7 (Figures 3B and
3D) were obtained. In addition, a 1H-1H DQF-COSY spectrum
was taken for IP6 (Figure S1B, see the Supplemental Data).
The pair of doublets in the 1H-decoupled 31P spectrum of IP7 at
9.0and10.2ppmshowthecouplingbetween theaandbphos-
phorous of the pyrophosphate group in IP7 (Figure 3B). The peaks
with positive values of chemical shifts represent the rest of the ino-
sitol ring containing phospho-monoester bonds. Comparison of
the 1H-decoupled 31P spectra for IP6 and IP7 reveals a shift of
thepeak foraP5, reflectingpyrophosphorylationat theC5position
of the inositol ring. The shift of the peak representing coupling
between H5 and aP5 nuclei is also evident by comparison of the
gHMBCspectra of IP6 and IP7 (Figures3Cand3D;
1H-31PgHMBC
spectra do not record H/bP coupling). These spectra provide un-
ambiguous evidence that IP6K1 attaches a b-phosphate to the
aP5-phosphate group of IP6. The structure of IP7 is thus 5-PP-
IP5, as suggestedpreviously from the
1H-decoupled 31P spectrum
of IP7 synthesized by human IP6K1 (Mulugu et al., 2007).5, 274–286, March 2008 ª2008 Elsevier Ltd All rights reserved 277
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Catalytic Promiscuity of IP6KFigure 3. Structures of IP6 Derivatives Generated by IP6K
(A and B) 1H-decoupled 31P spectrum of (A) pure IP6 (2 mM) and (B) HPLC-purified IP7 synthesized by IP6K1 (5-PP-IP5; 1 mM).
(C–G) 1H-31P gHMBC spectra: the numbers above the peaks mark the positions of the a-phosphate (aP) groups around the inositol ring: (C) Pure IP6; (D) HPLC-
purified IP7 synthesized by IP6K1; (E) IP7 synthesized by an IP6K2: assay mixture (12 hr at 37
C) in cacodylate buffer (1 mM IP6, 0.4 mM IP7). HPLC-ICP-MS278 Chemistry & Biology 15, 274–286, March 2008 ª2008 Elsevier Ltd All rights reserved
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Catalytic Promiscuity of IP6KFigure 3. Continued
analysis of the sample is inserted. (F) HPLC-purified IP8 (0.2 mM) synthesized by IP6K1. (G) IP6K2 assay with IP6 in Tris buffer (12 hr at 37
C) (0.3 mM IP6, 1 mM
IP7, 0.1 mM IP8). HPLC-ICP-MS analysis of the sample is shown in the inset.
(H) 1H-decoupled 31P spectrum of HPLC-purified IP8 synthesized by IP6K1. The specific position of the multiple peaks belonging to the b-phosphate group of IP8
triphosphate is marked by a dotted circle.
(I) Bottom: 1H-decoupled 31P spectra of the IP6K2 assaymixture with IP6 in Tris buffer (the same sample as in [G]), before () and after (+) addition of ATP (1.5mM).
Both spectra are magnified twice for better resolution of the peaks describing pyrophosphate (6 to12 ppm) and triphosphate (21 ppm) groups. Structures
of IP6 and its derivatives are shown; the white and black balls attached to the inositol ring represent the phosphate groups.Chemistry & Biology 15, 274–286, March 2008 ª2008 Elsevier Ltd All rights reserved 279
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Catalytic Promiscuity of IP6KFigure 4. Structures of IP5 Derivatives Generated by IP6K2
(A) Left: 1H-31P gHMBC spectrum of pure IP5 (5.2 mM). Right: part of the
1H-decoupled 31P spectrum for comparison with the rest of the spectra in the figure.
(B–D) Left: 1H-31P gHMBC spectrum with inserted HPLC-ICP-MS analysis of the sample; right: region on the 1H-decoupled 31P spectrum with peaks describing
pyrophosphate groups. (B) Determination of the structure of A1 (5-PP-IP4). The IP5 assay mixture (4 hr at 37
C) in cacodylate buffer (4 mM IP5, 3 mM A [A1],280 Chemistry & Biology 15, 274–286, March 2008 ª2008 Elsevier Ltd All rights reserved
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Catalytic Promiscuity of IP6KThe stereochemistry of IP7 synthesized by IP6K2 was also de-
termined. To avoid tedious preparation of the large amount of
pure IP7 needed for NMR analysis, the assay mixture was
analyzeddirectly (Figure 3E). The assaywas carried out in a caco-
dylate buffer to prevent the formation of IP8 and thus reduce the
number of compounds contributing to the spectra (Figure 3E).
The molecules in the sample containing phosphate groups were
phosphoenolpyruvate (PEP), IP6, and IP7. Using the information
obtained fromthespectraof pure IP6 (Figures3Aand3C), IP7 (Fig-
ures3Band3D), andPEPatpH6.0 (datanot shown), thestructure
of IP7 synthesized by IP6K2 was determined to be 5-PP-IP5.
IP7 made by IP6K3 was also analyzed by NMR. Due to the
lower activity of this isoform, an assay mixture with IP6 in Tris
buffer contained IP7 as the only product, and its structure was
found to be 5-PP-IP5 (data not shown).
IP8 Synthesized by IP6Ks from IP6
Is a Triphosphate: 5-PPP-IP5
The IP8 produced by IP6K is a minor species compared with IP7
(Figures 1 and 2). However, depending on the assay conditions,
theconversion of IP6 to IP8 in vitro varies from0%to30% (Figures
2A and 3G; Figure S5B). NMR spectra were first collected on
HPLC-purified IP8 synthesized by IP6K1 (Figures 3F and 3H).
Mass analysiswasdonewith the same sample (Table 1), showing
that IP8 contains two phosphate groups more than IP6. gHMBC
spectra of IP7 and IP8 are similar (Figures 3D and 3F), suggesting
that IP8 is a triphosphate since no a-phosphate group other than
that of aP5 is additionally phosphorylated. This is also clear from
the positions of the peaks in the 1H-decoupled 31P spectrum
of IP8 (Figure 3H). This spectrum contains two doublets at
4.3 ppm and10.2 ppm, and amultiplet at20 ppm, assigned
as gP5, aP5, and bP5 respectively. Accordingly, IP8 made by
IP6K1 is 5-PPP-IP5.
Next, we examined the structure of IP8 synthesized by IP6K2.
The IP6K2 assay mixture was prepared in Tris buffer, thus
enabling the formation of IP8 (Figures 3G and 3I). Nucleotides
were removed prior to NMR data collection by charcoal treat-
ment. The sample contained IP6, IP7, and IP8; with IP8 repre-
sented 10% of the mixture (Figures 3G and 3I). The structure
of IP8 made by IP6K2 (5-PPP-IP5) was extracted with the help
of the known spectra for pure IP6, IP7, and IP8. Figure 3I shows
the 1H-decoupled 31Pspectrumof themixture,where themultiple
peaks (triplet) at20.7 ppm are assumed to belong to bP5 of IP8.
To ensure that this triplet peak is not due to any remnant ATP,
even after charcoal treatment, fresh ATP was added to the sam-
ple to a final concentration of 1.5mM, and another 1H-decoupled
31P spectrum was collected (Figure 3I, ATP [+]). Comparison of
spectra before and after the addition of ATP clearly shows that
the triplet at 20.7 ppm belongs to the bP of the triphosphate
group of IP8 (5-PPP-IP5), and that the triplet at 21.7 ppm be-
longs to the bP of the triphosphate group of ATP. The spectra
of a mixture containing higher concentrations of IP8 (30% of allChemistry & Biology 1IPspresent)wereobtained (FiguresS5BandS5C), again confirm-
ing the presence of a C5 triphosphate group in IP8.
With IP6K3, IP8 could not be obtained in the quantity needed
for NMR analysis. Since its IP8 elutes with the same retention
time as IP8 made by the other two IP6K isoforms (Figure 2A),
IP6K3 presumably synthesizes IP8 of the same structure as
synthesized by IP6K1 and IP6K2.
IP5 Derivatives Synthesized by IP6Ks Contain
Pyrophosphate as Well as Triphosphate Groups
Since all three IP6Ks show the same activity toward IP5 (Figures
1D and 2B), IP6K2 was used as the representative enzyme to
synthesize IPs for structural analysis, as it has the highest protein
yield. Structures of IP5 derivatives were determined by using
spectra of pure IP5 and of IP5 in assay mixtures prepared in
cacodylate and in Tris buffer.
The assay mixture prepared in cacodylate buffer contains IP5
and product A as the only two IPs (Figure 4B). Mass analysis of
this sample suggests that A is once-phosphorylated IP5 deriva-
tive (Table 1). A is not IP6, because the spectra of the IP5/A mix-
ture (Figure 4B) show no formation of phospho-monoester at the
C2 position of IP5 (no peak for H2/aP2 coupling in the gHMBC
spectrum). In addition to peaks for IP5 (see Figure 4A, left, for
comparison), there is, however, a newpeak in this spectrum (Fig-
ure 4B, left), indicating the presence of a pyrophosphate group,
similar to IP7. The
1H-decoupled 31P spectrum of A obtained by
subtraction of the 1H-decoupled 31P spectrum of IP5 from the
corresponding spectrum of the IP5/A mixture (Figure S7A, peaks
in blue) reveals that A contains a pyrophosphate group at the C5
position. The doublets for aP5 and bP5 of A are positioned at
10.5 ppm and9.5 ppm, respectively (Figure 4B, right). There-
fore, A is 5-PP-IP4.
Spectra of the IP5 derivatives prepared in Tris buffer are more
complex. HPLC-ICP-MS analysis as well as ESI-MS of the sam-
ple revealed three compounds of increasing polarity: A with one,
B with two, and C with three additional phosphate groups
attached to IP5 (Figure 4C; Table 1). The gHMBC spectrum
shows that in the IP5/A/B/C mixture, the pyrophosphate bonds
are present in at least two different positions (Figure 4C). These
are C1 (or its enantiomer C3) and C5, based on vertical shifts of
the peaks in the gHMBC spectrum relative to the spectra of IP5
(Figure 4A) and the IP5/A mixture (Figure 4B). Similar spectra
showing the simultaneous presence of pyrophosphate groups
at C1(3) and C5 have been determined by Laussmann et al.
(1998) for 1(3),5-[PP]2-IP4 from amoeba. In addition, the highest
intensity of the peak in the gHMBC spectrum describing H4(6)/
aP4(6) coupling is due to the contribution of the monophop-
shorylated C4(6) positions of all IPs present within this mixture
(Figure 4C).
To determine which peaks in the spectra of the IP5/A/B/C mix-
ture belong to 5-PP-IP4, half the volume of the IP5/A mixture
(Figure 4B) was added to half the volume of the IP5/A/B/C mix-
ture (Figure 4C). The increase in the concentration of 5-PP-IP40.01 mM B). Peaks belonging to aP5 and bP5 of A1 are in blue. (C) The IP5 assay mixture (4 hr at 37
C) in Tris buffer (0.6 mM IP5, 3.5 mM A [A1+A2], 2.3 mM B
[B1+B2], 0.4 mM C). Peaks belonging to aP5/bP5 of A1 are in blue, and those belonging to aP1(3)/bP1(3) of A2 are in red. (D) Half the volume of the mixture de-
scribed in (B) was added to half the volume of the mixture described in (C). The change in the intensity of peaks belonging to A1 (blue) due to the increased con-
centration of this compound is evident. The HPLC-ICP-MS analysis of this new mixture is shown in the inset. Determined structures of IP5 derivatives are de-
picted. For clarity, 3-PP-IP4 (A2 enantiomer) and 3,5-[PP]2-PP3 (B1 enantiomer) are not shown.5, 274–286, March 2008 ª2008 Elsevier Ltd All rights reserved 281
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spectrum describing this compound (Figure 4D).
The low intensity of the peaks belonging to 5-PP-IP4 in the
original IP5/A/B/C mixture (Figure 4C) is in contrast to the
HPLC-ICP-MS profile of the sample, where A is the major com-
pound. Therefore, the sample must contain another compound
of a similar polarity as 5-PP-IP4, but of a higher concentration.
Based on our observation that IP6K also forms pyrophosphate
bonds on IP5 at C1(3), the structure is 1-PP-IP4 (and/or its enan-
tiomer 3-PP-IP4). The highest peaks in the one-dimensional
spectrum (Figure 4C) therefore belong to 1(3)-PP-IP4 (also
named A2). 5-PP-IP4 (also A1) and A2 together elute in the highest
peak of the HPLC-ICP-MS profile, with A1 as a minor (20%) and
A2 as a major (80%) fraction.
The HPLC-ICP-MS elution profile (Figure 4C) and mass analy-
sis (Table 1) of the IP5/A/B/C sample reveal a significant amount
of compound B, with two additional phosphate groups attached
to IP5. Since pyrophosphorylation of IP5 at positions C1 and/or
C3 and C5 seems to be favored by IP6K, the structures for B
are 1,5-[PP]2-IP3 (and/or 3,5-[PP]2-IP3) (B1) and 1,3-[PP]2-IP3
(B2). The peaks corresponding to all of these isomers of B can
be assigned in the 1H-decoupled 31P spectrum (Figure 4C; Fig-
ure S8). Due to the symmetric structure of B2, aP1 and aP3 are
described with a doublet at11.2 ppm, and bP1 and bP3 are de-
scribedwith a doublet at8.7 ppm. Since B2 is a derivative of A2,
Table 1. ESI-MS Analysis of IP5-and IP6-Derivatives Synthesized
by IP6K
Inositol
Phosphate m/z
Molecular Ion
Adducts in
Positive Mode
Molecular Ion
Adducts in
Negative Mode
M(IP5)
a = 580
MS 579 [IP5H]
M(A)b = 660
MS 659 [AH]
M(B)b = 740
MS 739 [BH]
M(C)b = 820
MS 819 [CH]
M(IP6)
a = 660
MS 661 [IP6+H]
+
M(IP7)
c = 740
MS 741 [IP7+H]
+
M(IP8)
c = 820
MS 821 [IP8+H]
+
a Pure IP5 or IP6 was used.
b The sample used for NMR from the assaymixture prepared in Tris buffer
was analyzed (Figure 4C). The samemass for product A was obtained for
the NMR sample prepared from the assay mixture in cacodylate buffer
(Figure 4B). The mass of the compound that equals the mass of IP5
plus one phosphate group was assigned to product A, the mass with
two extra phosphate groups was assigned to product B, and the mass
with three phosphate groups was assigned to product C, according to
their increasing retention times in the chromatographic profiles (Figures
1 and 2).
c Purified IP7 or IP8 was analyzed after NMR (Figure 3). The samples were
desalted before ESI-MS analysis.282 Chemistry & Biology 15, 274–286, March 2008 ª2008 Elsevier Lpeaks belonging to B2 pyrophosphate groups almost merge with
the corresponding peaks of A2 (Figure 3C; Figure S8B). B1 con-
tains pyrophosphate bonds at C1(3) andC5 and can therefore be
considered as a ‘‘hybrid’’ of A1 and A2. Indeed, the doublet for
aP1(3) of B1 is close to that of aP1(3) of A2, and the doublet of
bP1(3) of B1 is close to that of bP1(3) of A2. The doublet for
aP5 of B1 is in close proximity to that of aP5 of A1, and the dou-
blet for bP5 of B1 is close to the doublet of bP5 of A1 (Figure 3C).
Similar to the IP8 spectrum, a multiplet of peaks in the
1H-de-
coupled 31P spectrum of the IP5/A/B/C mixture is present at
22 ppm (Figure S8C). This multiplet consists of at least five
peaks, which could represent two merged triphosphate groups,
one belonging to ATP and one to an IP compound. Based on the
intensity of the multiplet and on mass analysis, this triphosphate
group might belong to compounds eluted in peak C, which, be-
sides the triphosphate group, contain a pyrophosphate group at
another position on the inositol ring (Figure 4C; Figure S8C; Table
1). Several smaller doublet peaks in the region from8.5 ppm to
11.5 ppm that could belong to the C isomers support this
assumption (Figure 4C; Figure S8C). Interestingly, compound
C elutes close to IP8, which itself is a triphosphate (Figure 2B).
DISCUSSION
IPs containing phospho-anhydride bonds of high energy (PP-IPs)
represent a relatively young branch in cell-signaling research. In
spite of many, mostly technical, obstacles in the study of these
intriguing molecules (Irvine and Schell, 2001; Shears, 2004),
knowledge of the evolution and functions of PP-IPs and the
enzymes involved in their metabolism has recently developed
at an encouraging rate (Bennett et al., 2006; Shears, 2007).
Cells contain structurally diverse, yet nonredundant, PP-IPs,
each carrying out their own specific functions (reviewed in
Bennett et al., 2006; Shears, 2007). Although the structures of
the PP-IPs present in slime molds have been known for some
time (Laussmann et al., 1998), information onmammalian PP-IPs
has been scarce. To elucidate this missing piece, the main goal
of this study has been to determine the structures of PP-IPs
synthesized by the mammalian PP-IP synthase, IP6K.
Mammalian IP6K isoforms (IP6K1, IP6K2, IP6K3) share up to
65% amino acid similarity (Saiardi et al., 2001a), which is, as
shown here, sufficient for comparable kinase activity both
in vivo and in vitro. Differences in their amino acid sequences
are mostly confined to the N-terminal halves of the polypeptide
chains and to a patch of 40 residues in the C-terminal half of
the protein, following the highly conserved and catalytically
important sequence SSLL (Saiardi et al., 2001a). Interestingly,
some amino acids from this 40 residue region are responsible
for the specific interaction of IP6K2 (but not IP6K1 or IP6K3)
with TRAF2 that plays a role in the proapoptotic function of
IP6K2 (Morrison et al., 2007). However, only IP6K1 interacts
with GRAB, a protein involved in vesicle exocytosis (Luo et al.,
2001). These isoform-specific interactions with other proteins
seem to be independent of kinase activity. Therefore, whereas
the three mammalian IP6Ks synthesize the same panel of
PP-IPs, the specificity of function is determined by independent
protein-protein-based interactions and by differences in tissue
and intracellular distribution between the isoforms.td All rights reserved
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Catalytic Promiscuity of IP6KFigure 5. IP5 and IP6 Derivatives Synthesized by IP6K
Gray background: structures of products determined in this study (IP7, IP8, A, B). White background: C*: proposed structures of IP5 derivative C (all possible
isomers). IP9**: hypothetical structure of IP6 derivative IP9. Phosphate groups added by IP6K to the substrates are marked with black balls.Figure 5 is summarizing the structural features of PP-IPs syn-
thesized by IP6Ks, as determined in this study. When IP6 is used
as a substrate, IP6K attaches the phosphate group only at the C5
position of the inositol ring, resulting in the formation of 5-PP-IP5
(IP7). IP6K can further phosphorylate IP7 to 5-PPP-IP5 (IP8).
Chromatographic, mass, and NMR analyses of the IP6K/IP6 as-
say mixtures (Figure 3) show that IP7 is the major product and
that IP8 is the minor product. The ratio between them varies
from 90:10 to 70:30 and is similar under both in vivo and in vitro
conditions. Our results therefore suggest that 5-PP-IP5 and
5-PPP-IP5 are physiologic intracellular products (Figure 1).
Themost striking result is that IP8 synthesizedby IP6Ks from IP6
in vitro is a triphosphoinositol pentakisphosphate (5-PPP-IP5),
and not bis-diphosphoinositol tetrakisphosphate, as suggested
previously (reviewed in Bennett et al., 2006). However, 5-PPP-
IP5 is not the only IP8 isomer made by IP6Ks in cells, as two iso-
mers of IP8 were detected in vivo (Figures 1A–1C). Mulugu et al.
(2007) showed that IP6K converts 4(6)-PP-IP5, made by the
kinase Vip1, to another isomer of IP8, presumably 4(6),5-[PP]2-Chemistry & Biology 1IP4. Although this may be an explanation for the existence of the
second (IP8B) isomer in the wild-type and kcs1D yeast, the exis-
tence of the IP8B peak in vip1Dkcs1D yeast is intriguing (Figures
1A–1C).Onepossibility is that theyeastgenomecodes for another
IP6/IP7 kinase not detected to date. Whereas mammalian cells
contain two Vip1-like kinases, only one (Vip1) has been shown
thus far in yeast (Mulugu et al., 2007; Fridy et al., 2007; Choi
et al., 2007). Another explanation could be that IP6K itself synthe-
sizes the IP8B isoform.A longer incubation timeof the in vitroassay
shows the formation of the IP8 (IP8A) peak with a shoulder that
overlaps with the IP8B peak (Figure 1A). However, no other IP8
isoform but 5-PPP-IP5 was detected in our NMR analyses.
The promiscuity of IP6K’s active site reaches yet another level
when IP5 is utilized as a substrate. Under in vitro conditions used
in this study, IP6Ks convert IP5 to several products faster and
more consistently than IP6. The higher solubility of IP5 and its de-
rivatives compared with IP6 and its derivatives may contribute to
this phenomenon. Substantial conversion of IP5 also occurs in
yeast cells overexpressing IP6K2 (Figure 1D).5, 274–286, March 2008 ª2008 Elsevier Ltd All rights reserved 283
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were all determined from the assay mixture by using the decon-
volution strategy (Figure 4). The advantage of such a rather com-
plex analysis is that by comparison of the intensity of the peaks
belonging to particular IP5 derivatives we can estimate their ratio
in the solution, which cannot be done solely based on chromato-
graphic analysis due to the similar polarity of some of the com-
pounds. Here, we show that IP6K phosphorylates IP5 at the C1
and/or C3 and C5 positions. The free axial C2-hydroxyl group
of IP5 allows for several different binding modes of IP5 in the ac-
tive site of IP6K, at the same timeprotecting itself fromphosphor-
ylation. NMR analysis shows that after 4 hr of incubation at 37C
(Figure 4C), product 1(3)-PP-IP4 A (A2) dominates largely over 5-
PP-IP4 (A1). Products B1 (1(3),5-[PP]2-IP3) and B2 (1,3-[PP]2-IP3)
are made approximately at the same level, although at a lower
concentration than A2 and at a higher concentration than A1.
These structures, together with the data from Figure 2D, suggest
that A isomers are formed directly from IP5, B isomers are formed
directly fromA,C isomers are formeddirectly fromB, and that the
ratio between them varies with time.
Figure 5 also shows structures for the IP6-or IP5-derivatives
(such as IP9 and C isomers) that are only hypothetical. These mi-
nor products have been detected by chromatographic and/or
mass analyses, and they could not be resolved by NMR studies.
The time course for in vitro formation of products by IP6K sug-
gests stepwise phosphorylation events, i.e., when the first prod-
uct is formed, it is used as a substrate for the formation of a more
polar product by the same active site. The phosphorylation sites
on the inositol ring determined in our studies (C1, C3, and C5)
suggest that the newly formed product must first diffuse out of
the active site and later rebind in the mode appropriate for the
formation of another pyrophosphate bond at a different position
on the inositol ring. The mechanism of formation of the triphos-
phate groupmight bemore complex, because the elongated pol-
yphosphate chain may make it difficult for the inositol ring to fit
into the ‘‘typical’’ (conserved) inositol-binding site. Perhaps there
is an additional region in the enzyme that enlarges the conserved
inositol-binding domain to enable the triphosphate extension.
Partial inhibition of IP6K by cacodylate is an interesting phe-
nomenon. Chemically, cacodylate is a dimethylarsenate, with
a structure that mimics that of phosphate and sulfate ions. Caco-
dylate has been shown before to bind to the phosphate-binding
region of the enzyme’s active site (Shenoy et al., 2007). In addition,
in the crystal structure of apo-IP3K, sulfate ions (e.g., phosphate
analog) were found to bind to the active site and are replaced
upon binding of the substrate by its phosphate groups (Gonzalez
et al., 2004). Similar competition of cacodylate with IPs and
ATPmay therefore happen in the active site of IP6K. Another pos-
sibility is that cacodylate binds covalently to the serine or cysteine
side chains, thereby affecting the activity of the enzyme (Goldgur
etal., 1998;Zhuetal., 2003).Bybindingviaeitherof these twopos-
siblemodes, cacodylate affects the size and the shapeof the IP6K
active site. The modified active site now allows IP5 or IP6 to bind
only in an orientation that leads to pyrophosphorlyation at position
C5. Binding of IP5 in an orientation that leads to C1/3 pyrophos-
phorylation is prohibited. In addition, there is no room in this active
site for further phosphorylation to a triphosphate group.
This study demonstrates IP6K’s ability to form several diphos-
pho- and triphospho-IP derivatives from IP5 and IP6. Further-284 Chemistry & Biology 15, 274–286, March 2008 ª2008 Elsevier Lmore, in vitro as well as in vivo, even more polar peaks than IP8
can be observed due to IP6K activity. Whether these represent
the synthesis of yet another diphosphate group around the ring
or even further extension of the existing triphosphate group
(i.e., IP9 with the structure 5-PPPP-IP5) is unclear. Knowing
whether the active site is broad or flexible enough to accommo-
date different substrates, or if the enzyme uses different phos-
phorylation mechanisms dependent on the substrates, requires
three-dimensional structural analysis of IP6K.
SIGNIFICANCE
IPs are important cellular signaling molecules. Among the
manyderivatives, themost intriguing are theones containing
highly energetic phospho-anhydride bonds (PP-IPs). Al-
though PP-IPs have been relatively less appreciated by the
cell-signaling community, recent information on the synthe-
sis and function of these molecules shows that they may
have a wider role in cell physiology than previously under-
stood (Bennett et al., 2006; Shears, 2007). However, informa-
tion on the structures of these molecules, especially those
present inmammalian cells, hasbeen largelymissing. There-
fore, the main focus of our study was to decipher the struc-
tures of PP-IPs synthesized from IP5 and IP6 by the three
mammalian IP6K isoforms. Our results reveal a group of
products derived from both substrates, generated equally
by all three IP6K isoforms in vivo and in vitro. These include
IP5-and IP6-derivatives with pyrophosphate and/or triphos-
phate groups. The structures of PP-IPs shown in this work
can serve as starting points for the elaboration of synthetic
PP-IPs by organic chemists, compounds that have been
awaited by biologists studying themetabolism and signaling
of IPs and PP-IPs. Moreover, since these compounds are in-
volved in many physiologic and pathologic processes
(reviewed in Bennett et al., 2006; Shears, 2007; Piccolo
et al., 2004;Maffucci et al., 2005), they can also serve as leads
for drugdiscovery or as pharmacological probesof signaling
pathways.
EXPERIMENTAL PROCEDURES
Expression of IP6Ks in Yeast and Analysis of IPs
Mammalian IP6Ks were cloned in a high-copy number yeast plasmid, and their
expression was driven by the constitutive Alcohol Dehydrogenase (ADH) pro-
moter. The open reading frames (ORFs) for IP6K1, IP6K2, and IP6K3 were ob-
tained by SalI-NotI digestion of pCMV-IP6K1 and pCMV-IP6K2 (Saiardi et al.,
1999) and by SalI digestion of pGST-IP6K3 (Saiardi et al., 2001a) and were
subcloned in the yeast expression vector pADH. pADH was derived from
pYes2NTA (Invitrogen) by substitution of the hexahistidine fusion expression
cassette with a GST fusion expression cassette from pGEX4T-2 (GE Health-
care, Sweden) by using PCR and HindIII and PmeI as cloning sites; the Gal4
promoter was subsequently substituted by the ADH promoter obtained by
genomic PCR, by using SpeI and HindIII as cloning sites. Plasmids were trans-
formed into kcs1D and ipk1Dkcs1DS. cerevisiae derived from the BY4741 par-
ent strain (Saiardi et al., 2002). vip1Dkcs1D double mutant yeast (parental
strain DDY1810) were generated by using standard homologous recombina-
tion techniques (Gu¨ldener et al., 1996, 2002).
HPLC analysis of IPs was performed as previously described (Azevedo and
Saiardi, 2006) (for a detailed description, see the Supplemental Data). Prepa-
ration of recombinant IP6Ks from E. coli and enzyme assays (radioactive and
nonradioactive) are also described in the Supplemental Data.td All rights reserved
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HPLC-ICP-MS analysis of the nonradioactive samples was carried out by us-
ing reversed-phase ion-pairing chromatography on a Zorbax Eclipse XDB-C8
column (2.13 100 mm, 3.5 mm) at 0.2 ml/min. Isocratic elution was performed
by using a mixture of 40%–50% Buffer A (20 mM di-ammonium hydrogen cit-
rate, 1.5 mM tetra-butyl-ammonium hydroxide (TBAH), and 2% [v/v] methanol)
and 60%–50% Buffer B (20 mM di-ammonium hydrogen citrate, 1.5 mM
TBAH, and 16% [v/v] methanol) on an Agilent 1100 series HPLC to give reason-
able resolution between the peaks. Buffers A and Bwere adjusted to pH 6.0 by
the addition of 1 M ammonia solution. The column was connected to the Agi-
lent 4500 ICP-MS, where the phosphorus signal at m/z ratio 31 was recorded.
NMR Analysis
Preparation of the samples is described in the Supplemental Data. Samples
were transferred either into regular or Shigemi 5 mm diameter NMR tubes.
All NMR spectra were acquired at 283K by using the Unity Inova Varian
300 MHz system equipped with a 5 mm Indirect Detection Pulsed Field Gradi-
ent probe and an Automation Triple Resonance Broadband probe. 1H chem-
ical shifts were referenced to water (4.80 ppm), and 31P chemical shifts were
referenced to external phosphoric acid (0 ppm). Spectra were processed
and analyzed by using VNMR 2.1B (VARIAN, Inc.) software.
For 1H-decoupled 31P spectra, 90 degree excitation pulses of 7.6 ms and re-
covery delays of 1 swere employed, with 32,768 complex points and a spectral
width of 13.5 kHz, resulting in digital resolution of 0.4 Hz/point. For 1H decou-
pling, the WALTZ-16 technique was employed. The number of transients was
8000.
1H-31P gHMBC spectra were recorded with 4096 complex points in the t2 di-
mension, 256 increments in the t1 dimension, and a spectral width of 3.5 kHz in
F2 and 5.3 kHz in F1. The number of transients per free induction decay was
320. Recovery delay between experiments was 1.5 s. Appropriate delays
were calculated from nJPH = 7.7 Hz.
Assignment of spectra was based on detailed analysis of spectral features
and correlations between 1H-decoupled 31P and gHMBC NMR experiments.
Individual resonances were assigned on the basis of their chemical shifts,
signal intensities, and the multiplicity of resonances.
All NMR data were collected at the Slovenian NMR Centre at the National
Institute of Chemistry Slovenia.
Mass Analysis
The mass analysis experiments were conducted on an ion trap LCQ MS sys-
tem (Finnigan, MAT, San Jose, CA, USA). Mass spectra were recorded with
direct injection (20 ml/min) of the sample with amakeup flow of 80% (v/v) meth-
anol in water at 0.2 ml/min. ESI-MS in positive or negative polarity mode was
used. The transfer capillary temperature was 200C, source voltage was
4.0 kV, and sheath gas pressure was 345 kPa.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, NMR
spectra in an enlarged format with detailed peak assignments, and DQF-
COSY NMR spectra and are available at http://www.chembiol.com/cgi/
content/full/15/3/274/DC1/.
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